Robin Lucas, MD
Pulmonary Disease · Somerset, NJNPI 1841286697
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,900 of the $16,458 with a category attached, or 60.2%. AstraZeneca accounts for 77.0% of it on its own, with 25 other manufacturers making up the rest. Among pulmonary disease clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $53.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$13K
- GSK$1K
- Mylan Specialty L.p.$624
- Novo Nordisk$285
- Philips North America LLC$257
- Genentech USA, Inc.$239
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$9,90060%
- Travel & lodging$6754%
- Food & beverage$5,84836%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $12,677 |
| GSK | 64 | $1,160 |
| Mylan Specialty L.p. | 38 | $624 |
| Novo Nordisk | 20 | $285 |
| Philips North America LLC | 16 | $257 |
| Genentech USA, Inc. | 27 | $239 |
| United Therapeutics Corporation | 11 | $151 |
| Sanofi | 9 | $150 |
| Amgen | 6 | $98 |
| Sunovion Pharmaceuticals Inc. | 5 | $85 |
| Bayer | 5 | $82 |
| ANI Pharmaceuticals, Inc. | 5 | $80 |
| Novartis | 4 | $80 |
| Regeneron Healthcare Solutions, Inc. | 5 | $74 |
| Boehringer Ingelheim | 5 | $71 |
| Pfizer | 4 | $60 |
| Grifols USA, LLC | 3 | $50 |
| Abbott | 3 | $48 |
| Mallinckrodt Hospital Products Inc. | 3 | $41 |
| Merck | 2 | $34 |
| Lilly USA, LLC | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $27 |
| Dentsply Sirona Inc | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,458 in reported general payments places this provider in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LetairisAmbrisentan | 11 | $228,342 |
| Fasenra PenBenralizumab | 26 | $144,082 |
| EsbrietPirfenidone | 17 | $142,189 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 103 | $101,660 |
| Pirfenidone | 29 | $89,138 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 98 | $83,586 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $38,870 |
| Tadalafil | 14 | $25,266 |
| XareltoRivaroxaban | 18 | $24,483 |
| Spiriva RespimatTiotropium Bromide | 25 | $20,534 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $19,646 |
| EliquisApixaban | 21 | $17,768 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $12,513 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $9,339 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $8,519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadLetairis | $12 | $228,34211 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,160 | $160,176189 claims |
| Genentech USA, Inc.Esbriet | $239 | $142,18917 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $12,677 | $92,105126 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $71 | $29,87338 claims |
| Johnson & JohnsonXarelto | $14 | $24,48318 claims |
| PfizerEliquis | $60 | $17,76821 claims |
| MerckDulera | $34 | $7,52621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Somerset
- Lawrence DavanzoSomerset$26K
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
- Jeffrey MiskoffManasquan$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.